ArticleMolecular biomedicine2026
Epigenetically silencing gluconeogenic enzyme PCK1 by EZH2 promotes renal tubulointerstitial fibrosis.
Article in Molecular biomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
Chronic kidney disease (CKD) is a leading cause of global morbidity. The kidney is a major gluconeogenic organ, and impaired renal gluconeogenesis contributes to CKD, yet the regulatory mechanisms remain poorly understood. Here we show that enhancer of zeste homolog 2 (EZH2), a histone H3K27 trimethyltransferase, epigenetically suppresses renal gluconeogenesis and drives tubulointerstitial fibrosis. Through integrative multi-omics profiling (RNA-seq, CUT&Tag, and single-nucleus RNA-seq), we show that EZH2 directly binds to and deposits H3K27 trimethylation at promoters of gluconeogenic genes in proximal tubular cells, with the most prominent repression observed at phosphoenolpyruvate carboxykinase (Pck1) gene. In fibrotic kidneys, Ezh2 is markedly upregulated in proximal tubules and inversely correlates with Pck1 expression across injury and maladaptive repair states. Genetic ablation or pharmacological inhibition of EZH2 restores PCK1 expression, enhances lactate-to-glucose conversion, and attenuates extracellular matrix deposition and fibrotic marker expression in both cultured tubular cells and mouse models of kidney fibrosis. Stable isotope
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.